Acetic Acid

Acetic Acid

SCHEMBL6291027

CC(=O)O.CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccccc1)Oc1cccc(O)c1-3

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ESR1 known ✓ P03372 5/20 0.71
▸ ESR2 known ✓ Q92731 5/20 0.71
▸ NR3C1 P04150 16/20 0.74
▸ AR P10275 10/20 0.74
▸ NR3C2 P08235 9/20 0.74
▸ PGR P06401 14/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6294953 0.96 NR3C1 (0.80) NR3C1ARNR3C2PGRESR1
SCHEMBL6998522 0.88 NR3C1 (0.74) NR3C1ARNR3C2PGRESR1
SCHEMBL6291028 0.88 NR3C1 (0.79) NR3C1ARNR3C2PGRESR1
SCHEMBL6290327 0.87 PGR (0.78) NR3C1ARNR3C2PGRESR1
SCHEMBL6291168 0.85 NR3C1 (0.72) NR3C1ARNR3C2PGRESR1
SCHEMBL4171493 0.85 NR3C1 (1.00) NR3C1ARNR3C2PGRESR1
SCHEMBL6294460 0.85 NR3C1 (0.81) NR3C1ARNR3C2PGRESR1
SCHEMBL6294998 0.85 NR3C1 (0.75) NR3C1ARNR3C2PGRESR1
SCHEMBL6291115 0.85 PGR (0.78) NR3C1ARNR3C2PGRESR1
SCHEMBL6291126 0.85 NR3C1 (0.75) NR3C1ARNR3C2PGRESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073703-A1 Glucocortiocoid-selective antinflammatory agents ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED 2003-04-17 — — US claimed
EP-1299392-A2 GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS Abbott Laboratories (US) 2003-04-09 — — EP claimed
US-6506766-B1 A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid ABBOTT LABORATORIES 2003-01-14 — — US claimed
EP-1053239-B1 GLUCOCORTICOID-SELECTIVE ANTI-INFLAMMATORY AGENTS ABBOTT LAB (US) 2003-01-08 — — EP claimed
WO-2002002565-A2 GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 2002-01-10 — — WO claimed
US-6951942-B2 Glucocorticoid-selective anti-inflammatory agents ABBOTT LABORATORIES (US) 2005-10-04 — — US disclosed
US-20030073703-A1 Glucocortiocoid-selective antinflammatory agents ABBOTT LABORATORIES AND LIGAND PHARMACEUTICALS INCORPORATED 2003-04-17 — — US disclosed
EP-1299392-A2 GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS Abbott Laboratories (US) 2003-04-09 — — EP disclosed
US-6506766-B1 A pharmaceutical composition for use in treating inflammation, immune, autoimmune, and inflammatory diseases in a mammal by selectively modulating the activation, repression, agonism, and antagonism effects of the mammal's glucocorticoid ABBOTT LABORATORIES 2003-01-14 — — US disclosed
WO-2002002565-A2 GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 2002-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073703-A1 Glucocortiocoid-selective antinflammatory agents NR3C1, GPR119, MC2R ESR1 3937/4885ESR2 1581/4885NR3C1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback